We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Mice Developed to Secrete a Malaria Vaccine

By Biotechdaily staff writers
Posted on 20 May 2002
A study has demonstrated that an experimental malaria vaccine secreted by mice and injected into monkeys was able to protect four of five animals from a lethal dose of malaria. More...
Conducted by researchers at the US National Institute of Allergy and Infectious Diseases (NIAID) and Genzyme Transgenics Corp. (Framingham, MA, USA), the study was published in the December 18, 2001, online issue of the Proceedings of the National Academy of Sciences (www.pnas.org).

The researchers produced two transgenic mouse strains. Each carried a form of the gene for a surface protein from the deadliest malaria parasite, Plasmodium falciparum. The transgenes were designed to be switched on by cells that line the mammary glands, so that the resulting proteins would be secreted into the animals' milk. Both mouse strains produced large quantities of the desired vaccine, which was then used to vaccinate monkeys against malaria. Only one of the five immunized animals contracted malaria, while six out of seven unvaccinated animals had to be treated for virulent malaria.

The high yield of the protein and its ability to stimulate protective immunity in mice offers promising evidence that the same technique could also be used in goats or cows, say the researchers. Preliminary experiments suggest that the procedure works well in larger animals, a possibility that offers a far more practical option for large-scale production.

"A vaccine must not only be effective, it must be cheap to manufacture if it is to be used in those countries hit hardest by malaria,” said Anthony Stowers, Ph.D., lead author and a malaria researcher at NIAID. "Using transgenic animals to achieve both ends is an exciting possibility. If it works, a herd of several goats could conceivably produce enough vaccine for all of Africa.”




Related Links:
NIAID
Genzyme

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study results show blood protein levels change markedly in childhood and adolescence, with sex differences increasing with age (photo credit: Adobe Stock)

Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges

Serum proteins underpin many routine tests used to detect inflammation, hormonal imbalance, cardiovascular disease, and metabolic disorders. Yet pediatric interpretation often relies on adult reference... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.